Jazz reaffirms $4.25B-$4.5B 2026 revenue guidance while targeting an Aug. 25, 2026 PDUFA for Ziihera in GEA
Jazz Pharmaceuticals, Inc. · PHARMACEUTICAL PREPARATIONS · Now $232.64
-2.2% in 3d after detection
Post-detection moves
1h
—
1d
-0.7%
3d
-2.2%
7d
+0.1%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS